ey0015.8-11 | Clinical Trials – New Treatments | ESPEYB15
AM Isidori
, MA Venneri
, C Graziadio
, C Simeoli
, D Fiore
, V Hasenmajer
, E Sbardella
, D Gianfrilli
, C Pozza
, P Pasqualetti
, S Morrone
, A Santoni
, F Naro
, A Colao
, R Pivonello
, A. Lenzi
To read the full abstract: Lancet Diabetes Endocrinol. 2018; 6(3): 173-185Adrenal insufficiency (AI), caused by adrenal failure (primary) or hypothalamo-pituitary failure (secondary), has a prevalence of 250–450 per 1 million (16). AI is potentially life-threatening and requires lifelong glucocorticoid replacement therapy. Modified-release hydrocortisone preparations have bee...